胰腺癌根治术后行吉西他滨联合替吉奥化疗的临床分析

Clinical Analysis of Gemcitabine Combined Tegafur Chemotherapy after the Endotheration of Pancreatic Cancer

目的仔细分析胰腺癌根治术后行吉西他滨联合替吉奥化疗的临床分析。方法方便选择2016年3月-2019年3月收取的50例胰腺癌患者作为研究对象,按照抛硬币的方式分成对照组和观察组,各25例患者,其中观察组患者给予吉西他滨联合替吉奥化疗;对照组患者则是单独应用吉西他滨治疗。对比患者之间的治疗效果、生活质量评分、治疗依从性。结果对照组患者的治疗效果(64.0%)要低于观察组(92.0%),数据分析差异有统计学意义(P<0.05);观察组患者的生活质量评分优于对照组,两组患者的数据差异有统计学意义(t=8.261、9.215、8.665、15.216,P<0.05);对照组患者的依从性低于观察组差异有统计学意义(t=40.058、30.837、36.297、38.079,P<0.05)。结论针对临床胰腺癌患者给予吉西他滨联合替吉奥化疗,其治疗效果显著,值得进一步的应用推广。

Objective The purpose is to carefully analyze the clinical analysis of Gemcitabine combined Tegafur chemotherapy after the root treatment of pancreatic cancer. Methods Convenient selection of 50 pancreatic cancer patients collected between March 2016 and March 2019 were studied, and 25 patients in the control group and the observation group were divided into a coin toss, of which the patients in the observation group were given Gemcitabine joint Tegafur chemotherapy;Compare the treatment effect, quality of life score and treatment compliance between patients.Results The treatment effect of the patients in the control group was lower than that of the observation group(92.0%),and there were significant differences in data analysis(P<0.05), and the quality of life score of the patients in the observation group was better than that of the control group, and the data difference between the two groups was statistically significant(t=8.261、9.215、8.665、15.216,P <0.05). The compliance of the patients in the control group was lower than that of the observation group,the difference was statistically significant(t=40.058、30.837、36.297、38.079,P<0.05).Conclusion For clinical pancreatic cancer patients, the treatment effect is remarkable and should be further applied.